Last updated on November 2017

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus


Brief description of study

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Detailed Study Description

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Clinical Study Identifier: TX82055

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patient Recruitment

Cedar Crosse Research Center
Chicago, IL USA
  Connect »